Adenosine analogues and their use as pharmaceutical agents

US7265111B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Antony Bigot · Massy, FR
• Siegfried Stengelin · Frankfurt am Main, DE
• Gerhard Jaehne · Frankfurt, DE
• Andreas Herling · Bad Camberg, DE
• Guenter Mueller · Pocking, DE
• Franz Hock · Dieburg, DE
• Michael R. Myers · Fishers, US

Key dates

• Filing date: Jun 27, 2003
• Grant date: Sep 4, 2007
• Expiry date: Jan 26, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H19/16
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds according to the general formula (I)wherein X is selected from the group consisting ofwherein n and p are independently 0, 1, 2, or 3, provided that n+p is a least 1; These compounds are useful for the manufacture of a medicament for the treatment of insulin resistance, type 2 diabetes, metabolic syndrome, lipid disorders or cardiovasular disease or for providing an anti-lipolytic effect.